Analysis of Debt
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- Statement of Comprehensive Income
- Analysis of Solvency Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Present Value of Free Cash Flow to Equity (FCFE)
- Net Profit Margin since 2005
- Operating Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Current Ratio since 2005
- Price to Earnings (P/E) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Total Debt (Carrying Amount)
Regeneron Pharmaceuticals Inc., balance sheet: debt
US$ in thousands
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
The carrying amount of total debt exhibits a consistent, albeit modest, upward trend over the observed period. This analysis focuses on the components of total debt, specifically long-term debt and finance lease liabilities, to understand the drivers of this trend.
- Long-Term Debt
- Long-term debt demonstrates a steady incremental increase each year, moving from US$1,980,000 thousand in 2021 to US$1,985,900 thousand in 2025. The annual increase is consistently US$1,400 thousand. This suggests a pattern of regular, small-scale debt issuance or a consistent amortization schedule with limited principal repayments.
- Finance Lease Liabilities
- Finance lease liabilities are presented in two components: current and excluding current portions. In 2021, only the current portion was reported at US$719,700 thousand. Beginning in 2022, the non-current portion of finance lease liabilities is consistently reported at US$720,000 thousand and remains unchanged through 2025. The current portion is only reported for 2021, making trend analysis impossible. The introduction of the non-current portion in 2022 significantly expands the visibility into the company’s lease obligations.
- Total Long-Term Debt and Finance Lease Liabilities
- The combined carrying amount of long-term debt and finance lease liabilities increases incrementally from US$2,699,700 thousand in 2021 to US$2,705,900 thousand in 2025. The annual increase mirrors the increase in long-term debt, at US$1,400 thousand per year, as the non-current finance lease liability remains constant. This indicates that the growth in total debt is primarily driven by changes in long-term debt.
Overall, the company’s debt profile appears stable with a predictable pattern of incremental increases in long-term debt. The finance lease liabilities, once fully disclosed, contribute a consistent component to the total debt balance.
Total Debt (Fair Value)
| Dec 31, 2025 | |
|---|---|
| Selected Financial Data (US$ in thousands) | |
| Long-term debt | |
| Finance lease liabilities | |
| Total long-term debt and finance lease liabilities (fair value) | |
| Financial Ratio | |
| Debt, fair value to carrying amount ratio | |
Based on: 10-K (reporting date: 2025-12-31).
Weighted-average Interest Rate on Debt
Weighted-average interest rate on debt and finance lease liabilities:
| Interest rate | Debt amount1 | Interest rate × Debt amount | Weighted-average interest rate2 |
|---|---|---|---|
| Total | |||
Based on: 10-K (reporting date: 2025-12-31).
1 US$ in thousands
2 Weighted-average interest rate = 100 × ÷ =